Pharmacokinetics of levetiracetam after oral and intravenous administration of a single dose to clinically normal cats

Michelle Brogan Carnes Animal Specialty Hospital of Florida, 10130 Market St, Ste 1, Naples, FL34112.

Search for other papers by Michelle Brogan Carnes in
Current site
Google Scholar
PubMed
Close
 MS, DVM
,
Todd W. Axlund Ohio Veterinary Surgery and Neurology LLC, 1053 S Cleveland-Massillon Rd, Akron, OH 44321.

Search for other papers by Todd W. Axlund in
Current site
Google Scholar
PubMed
Close
 DVM, MS
, and
Dawn M. Boothe Department of Anatomy, Physiology and Pharmacology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849.

Search for other papers by Dawn M. Boothe in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To determine whether therapeutic concentrations of levetiracetam can be achieved in cats and to establish reasonable IV and oral dosing intervals that would not be associated with adverse effects in cats.

Animals—10 healthy purpose-bred cats.

Procedures—In a randomized crossover study, levetiracetam (20 mg/kg) was administered orally and IV to each cat. Blood samples were collected 0, 10, 20, and 40 minutes and 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours after administration. Plasma levetiracetam concentrations were determined via high-performance liquid chromatography.

Results—Mean ± SD peak concentration was 25.54 ± 7.97 μg/mL. The mean y-intercept for IV administration was 37.52 ± 6.79 μg/mL. Half-life (harmonic mean ± pseudo-SD) was 2.95 ± 0.95 hours and 2.86 ± 0.65 hours for oral and IV administration, respectively. Mean volume of distribution at steady state was 0.52 ± 0.09 L/kg, and mean clearance was 2.0 ± 0.60 mL/kg/min. Mean oral bioavailability was 102 ± 39%. Plasma drug concentrations were maintained in the therapeutic range reported for humans (5 to 45 μg/mL) for at least 9 hours after administration in 7 of 10 cats. Only mild, transient hypersalivation was evident in some cats after oral administration.

Conclusions and Clinical Relevance—Levetiracetam (20 mg/kg) administered orally or IV to cats every 8 hours should achieve and maintain concentrations within the therapeutic range for humans. Levetiracetam administration has favorable pharmacokinetics for clinical use, was apparently tolerated well, and may be a reasonable alternative antiepileptic drug in cats.

Abstract

Objective—To determine whether therapeutic concentrations of levetiracetam can be achieved in cats and to establish reasonable IV and oral dosing intervals that would not be associated with adverse effects in cats.

Animals—10 healthy purpose-bred cats.

Procedures—In a randomized crossover study, levetiracetam (20 mg/kg) was administered orally and IV to each cat. Blood samples were collected 0, 10, 20, and 40 minutes and 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours after administration. Plasma levetiracetam concentrations were determined via high-performance liquid chromatography.

Results—Mean ± SD peak concentration was 25.54 ± 7.97 μg/mL. The mean y-intercept for IV administration was 37.52 ± 6.79 μg/mL. Half-life (harmonic mean ± pseudo-SD) was 2.95 ± 0.95 hours and 2.86 ± 0.65 hours for oral and IV administration, respectively. Mean volume of distribution at steady state was 0.52 ± 0.09 L/kg, and mean clearance was 2.0 ± 0.60 mL/kg/min. Mean oral bioavailability was 102 ± 39%. Plasma drug concentrations were maintained in the therapeutic range reported for humans (5 to 45 μg/mL) for at least 9 hours after administration in 7 of 10 cats. Only mild, transient hypersalivation was evident in some cats after oral administration.

Conclusions and Clinical Relevance—Levetiracetam (20 mg/kg) administered orally or IV to cats every 8 hours should achieve and maintain concentrations within the therapeutic range for humans. Levetiracetam administration has favorable pharmacokinetics for clinical use, was apparently tolerated well, and may be a reasonable alternative antiepileptic drug in cats.

  • 1.

    Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004; 101: 98619866.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 2.

    Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol 2002; 136: 659672.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Hanon E, Klitgaard H. Neuroprotective properties of the novel antiepileptic drug levetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia. Seizure 2001; 10: 287293.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Wang H, Gao J, Lassiter TF, et al. Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 2006; 5: 7178.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000; 41: 12761283.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 6.

    Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236242.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 11791186.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Boon P, Chauvel P, Pohlmann-Eden B, et al. Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy. Epilepsy Res 2002; 48: 7789.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Glauser TA, Ayala R, Elterman RD, et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66: 16541660.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Sharpe DV, Patel AD, Abou-Khalil B, et al. Levetiracetam mono-therapy in juvenile myoclonic epilepsy. Seizure 2008; 17: 6468.

  • 11.

    Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 17511760.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402408.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 2001; 21: 13751388.

  • 14.

    Isoherranen N, Yagen B, Soback S, et al. Pharmacokinetics of levetiracetam and its enantiomer (R)-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 2001; 42: 825830.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Benedetti MS, Coupez R, Whomsley R, et al. Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 2004; 34: 281300.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Dewey CW, Bailey KS, Boothe DW, et al. Pharmacokinetics of a single-dose intravenous levetiracetam administration in normal dogs. J Vet Emerg Crit Care 2008; 18: 153157.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Moore SA, Munana KR, Papich MG, et al. Levetiracetam pharmacokinetics in healthy dogs following oral administration of single and multiple doses. Am J Vet Res 2010; 71: 337341.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995; 67: 351384.

  • 19.

    Volk HA, Matiasek LA, Feliu-Pascual AL, et al. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 2008; 176: 310319.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 20.

    Platt SR, Adams V, Garosi LS, et al. Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Vet Rec 2006; 159: 881884.

    • Search Google Scholar
    • Export Citation
  • 21.

    Dewey CW, Guiliano R, Boothe DM, et al. Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc 2004; 40: 285291.

  • 22.

    Bailey KS, Dewey CW, Boothe DM, et al. Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. J Am Vet Med Assoc 2008; 232: 867872.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 23.

    Bailey KS, Dewey CW. The seizuring cat: diagnostic work-up and therapy. J Feline Med Surg 2009; 11: 385394.

  • 24.

    Bazil CW. New antiepileptic drugs. Neurologist 2002; 8: 7181.

  • 25.

    Pucci V, Bugamelli F, Mandrioli R, et al. High-performance liquid chromatographic determination of levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed Chromatogr 2004; 18: 3744.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26.

    Martens-Lobenhoffer J, Bode-Boger SM. Determination of levetiracetam in human plasma with minimal sample pretreatment. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819: 197200.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 27.

    Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 2003; 54: 153161.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Steinhoff BJ, Somerville ER, Van Paesschen W, et al. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 2007; 76: 614.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 29.

    Thomas WB. Idiopathic epilepsy in dogs and cats. Vet Clin North Am Small Anim Pract 2010; 40: 161179.

  • 30.

    Quesnel AD, Parent JM, McDonell W. Clinical management and outcome of cats with seizure disorders: 30 cases (1991–1993). J Am Vet Med Assoc 1997; 210: 7277.

    • Search Google Scholar
    • Export Citation
  • 31.

    Dewey CW. Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Pract 2006; 36: 11071127.

  • 32.

    Cochrane SM, Parent JM, Black WD, et al. Pharmacokinetics of phenobarbital in the cat following multiple oral administration. Can J Vet Res 1990; 54: 309312.

    • Search Google Scholar
    • Export Citation
  • 33.

    Center SA, Elston TH, Rowland PH, et al. Fulminant hepatic failure associated with oral administration of diazepam in 11 cats. J Am Vet Med Assoc 1996; 209: 618625.

    • Search Google Scholar
    • Export Citation
  • 34.

    Hughes D, Moreau RE, Overal KL, et al. Acute hepatic necrosis and liver failure associated with benzodiazepine therapy in six cats (1986–1995). J Vet Emerg Crit Care 1996; 6: 1320.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 35.

    Podell M, Fenner WR. Bromide therapy in refractory canine idiopathic epilepsy. J Vet Intern Med 1993; 7: 318327.

  • 36.

    Boothe DM, George KL, Couch P. Disposition and clinical use of bromide in cats. J Am Vet Med Assoc 2002; 221: 11311135.

  • 37.

    Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 2006; 28: 734744.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 38.

    Doheny HC, Ratnaraj N, Whittington MA, et al. Blood and cere-brospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res 1999; 34: 161168.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 39.

    Loscher W, Honack D, Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998; 284: 474479.

    • Search Google Scholar
    • Export Citation
  • 40.

    Knake S, Gruener J, Hattemer K, et al. Intravenous levetiracetam in the treatment of benzodiazepine-refractory status epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588589.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 41.

    Mazarati AM, Baldwin R, Klitgaard H, et al. Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus. Epilepsy Res 2004; 58: 167174.

    • Crossref
    • Search Google Scholar
    • Export Citation

Advertisement